MALAT1: a therapeutic candidate for a broad spectrum of vascular and cardiorenal complications,Hypertension Research

当前位置： X-MOL 学术 › Hypertens. Res. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

MALAT1: a therapeutic candidate for a broad spectrum of vascular and cardiorenal complications
Hypertension Research ( IF 4.3 ) Pub Date : 2019-12-19 , DOI: 10.1038/s41440-019-0378-4
Prasanth Puthanveetil ₁ , Tony Gutschner ₂ , Johan Lorenzen ₃

Affiliation

Cardiovascular and renal complications cover a wide array of diseases. The most commonly known overlapping complications include cardiac and renal fibrosis, cardiomyopathy, cardiac hypertrophy, hypertension, and cardiorenal failure. The known or reported causes for the abovementioned complications include injury, ischemia, infection, and metabolic stress. To date, various targets have been reported and investigated in detail that are considered to be the cause of these complications. In the past 5 years, the role of noncoding RNAs has emerged in the area of cardiovascular and renal research, especially in relation to metabolic stress. The long noncoding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1) has shown immense promise among the long noncoding RNA targets for treating cardiorenal complications. In this review, we shed light on the role of MALAT1 as a primary and novel target in treating cardiovascular and renal diseases as a whole.

中文翻译：

MALAT1：广泛的血管和心肾并发症的治疗候选药物

心血管和肾脏并发症涵盖范围广泛的疾病。最常见的重叠并发症包括心脏和肾脏纤维化、心肌病、心脏肥大、高血压和心肾衰竭。上述并发症的已知或报道的原因包括损伤、缺血、感染和代谢应激。迄今为止，已经报道并详细研究了各种被认为是导致这些并发症的目标。在过去的 5 年中，非编码 RNA 在心血管和肾脏研究领域的作用已经显现，尤其是与代谢压力相关的研究。长链非编码 RNA MALAT1（转移相关肺腺癌转录本 1）在治疗心肾并发症的长链非编码 RNA 靶标中显示出巨大的前景。在这次审查中，

更新日期：2019-12-19

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11